MedPath

CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation

Not Applicable
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Procedure: automatic CT/MRI-US fusion system guided radiofrequency ablation
Registration Number
NCT04844112
Lead Sponsor
Seoul National University Hospital
Brief Summary

To prospectively evaluate the technical success rate of real-time computed tomography/CT/magnetic resonance imagingMR and -ultrasound (CT/MRI-US) automatic fusion system and the long-term therapeutic efficacy of radiofrequency ablation (RFA) guided by automatic fusion in hepatocellular carcinoma (HCC) patients.

Detailed Description

RFA is one of commonly used local therapies for primary or secondary liver tumors. For successful and safe procedure, safe route of electrode and lesion visibility are essential for RFA, and the conditions are usually evaluated on pre-RFA planning ultrasonography (USG). However, RFA is sometimes aborted due to limited sonic window of various cause and challenging identification of small isoechoic tumors or hepatocellular carcinomas among dysplastic nodules . Therefore, precise targeting and assuring safe route would be of clinical importance. In this preliminary study, investigators attempted to determine automatic US and CT/MR fusion technique would be able to improve RFA feasibility in patients with liver tumors.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
139
Inclusion Criteria
  • Pathologic or typical imaging based diagnosis of HCC
  • Multiphase CT or MRI within 3 months ahead of procedure
  • No evidence of distant metastasis
  • No contraindications for conventional RFA procedure in our institute, which are uncontrolled coagulopathy (international standard ratio ≥ 1.6, or platelet > 50,000), poor cooperation, unfeasible for sedation, portal vein tumor thrombus, tumor number >4, largest tumor size > 5cm, and tumors abutting portal vein or bile ducts bigger than segmental branches.
Exclusion Criteria
  • Lack of multiphase CT or MRI withing 3 months ahead of procedure
  • RFA planned for palliative purpose
  • Diagnosed as non-HCC malignancy
  • Right hepatectomy state

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Experimental armautomatic CT/MRI-US fusion system guided radiofrequency ablationpatients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
Primary Outcome Measures
NameTimeMethod
Technical success rate of the overall RFA procedureimmediately after RFA procedure

Absolute technical success rate of the overall RFA compared to literature

Rate of complete ablation of the tumor after 1 month clinical follow up1 month after the RFA procedure

Rate of complete ablation of the tumor after 1 month clinical follow up compared to literature

Technical success rate of the fusion processImmediately after fusion process

Absolute technical success rate of the fusion process

Secondary Outcome Measures
NameTimeMethod
Technical feasibility before and after the fusion process10 minutes after finishing planning USG

Technical feasibility recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.

Local tumor progression rateDuring post procedural follow up to 5 years

Local tumor progression rate after follow up compared to literature

Safety of the approach route before and after the fusion process10 minutes after finishing planning USG

Safety of the approach route recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.

Tumor visibility before and after the fusion process10 minutes after finishing planning USG

Tumor visibility recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.

© Copyright 2025. All Rights Reserved by MedPath